DEF 14A: Cryoport Seeks Stockholder Approval for Equity Incentive Plan Amendment Amidst Growth

Cryoport is asking stockholders to approve an amendment to its 2018 Omnibus Equity Incentive Plan to increase the number of authorized shares, citing company growth and the need to align employee incentives with stockholder value.

Summary

• Cryoport is soliciting proxies for its 2024 Annual Meeting of Stockholders to be held on May 17, 2024.
• Key proposals include the election of seven directors, ratification of Deloitte & Touche LLP as the independent auditor, approval of executive compensation, and an amendment to the 2018 Omnibus Equity Incentive Plan.
• The proposed amendment to the equity incentive plan seeks to increase the authorized shares by 2,500,000, from 7,850,000 to 10,350,000, to incentivize employees and align their interests with those of stockholders.
• In 2023, Cryoport achieved $233.3 million in revenue and supported a record 675 clinical trials in the regenerative medicine space.
• The company ended 2023 with $465.9 million in cash, cash equivalents, and short-term investments.
• Executive compensation includes base salary, annual cash incentives, performance-based stock options, and restricted stock rights, designed to motivate executives and enhance stockholder value.
• The Board recommends voting for all proposals.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While highlighting growth in certain areas and strategic initiatives, it also acknowledges challenges and missed financial targets. The overall tone is cautiously optimistic.

Positives

• The company is experiencing growth in the cell and gene therapy market.
• Cryoport is expanding its global presence and capabilities through strategic collaborations and acquisitions.
• The company has a strong cash position to execute its strategic goals.
• The executive compensation program is designed to align executive interests with stockholder value.
• The company has a high delivery success rate for temperature-controlled supply chain solutions.

Negatives

• The company experienced a significant drop in demand for cryogenic systems, particularly in China, in 2023.
• Growth for supply chain services solutions was slower than expected in 2023.
• The company did not achieve its revenue or Adjusted EBITDA targets for 2023, resulting in no bonus payouts for executives.
• The company's LTIR was 1.79 in 2023, compared to 1.23 in 2022.

Risks

• The company faces risks associated with changing economic conditions, supply chain constraints, and inflationary pressures.
• The company is subject to market acceptance risks and technical development risks.
• The company's future performance is not guaranteed and may differ substantially from expectations.
• The company's success depends on the health, talent, and dedication of its global team.

Future Outlook

The company anticipates up to 17 additional application filings, 9 new therapy approvals, and an additional 7 label/geographic expansions or moves to earlier lines of treatment approved during 2024.

Management Comments

• Jerrell Shelton, Chair, President & Chief Executive Officer: 'Our best days are ahead of us, and I look forward to continuing working with my teammates to create superior value for you, our long-term shareholders, by serving our important mission.'

Industry Context

Cryoport operates in the life sciences tools market, which has faced challenges due to macroeconomic and geopolitical environments. The company is positioning itself as an essential supply chain provider for the Cell & Gene Therapy industry, which is expected to accelerate its growth as manufacturing capacity increases and reimbursement modalities are established.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• However, it mentions that the company's adjusted gross usage of equity, which is the most comparable data point across companies, ranged from 1.5% to 1.9% over the past three years, which was at or below the peer group median of 1.9%.

Related Party Transactions

• Blackstone Freeze Parent L.P. holds a significant stake in Cryoport through Series C Preferred Stock and common stock.
• Ram M. Jagannath, designated by Blackstone Freeze Parent, serves on Cryoport's Board of Directors.
• Paid in-kind dividends paid to the Purchasers totaled $8.0 million for the year ended December 31, 2023.

Stakeholder Impact

• Shareholders: The proposed equity incentive plan amendment aims to align employee and executive interests with long-term shareholder value.
• Employees: The equity incentive plan is intended to attract, retain, and motivate employees.
• Customers: The company's focus on quality and reliability in its supply chain solutions benefits customers in the life sciences industry.
• Suppliers: The company expects its suppliers to share its commitment to ethics, integrity, compliance, safety, human rights, data security, and environmental protection.

Next Steps

• Stockholder vote on the proposed amendment to the 2018 Omnibus Equity Incentive Plan.
• Continued execution of strategic and tactical initiatives to fuel future growth.
• Continued focus on ESG policies and impact statements.
• Continued monitoring of the macroeconomic and geopolitical environment.

Key Dates

Keywords

Cryoport, equity incentive plan, proxy statement, executive compensation, annual meeting, cell and gene therapy, stockholders, directors, Deloitte, revenue, clinical trials, supply chain, biologistics, biostorage